Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02524119 · ClinicalTrials.gov registry record · Phase 2
LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02524119 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT02524119, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is determine whether the combination therapy with LEE011 and chemoembolization in patients with locally advanced Hepatocellular Carcinoma not amenable to curative therapies will provide greater efficacy than chemoembolization alone with a tolerable safety profile.
Interventions
- DRUG LEE011
- PROCEDURE Chemoembolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02524119
The ClinicalTrials.gov registry entry for NCT02524119 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LEE011 is the first listed.
NCT02524119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02524119 about?
NCT02524119 is a clinical study titled "LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma". The purpose of this study is determine whether the combination therapy with LEE011 and chemoembolization in patients with locally advanced Hepatocellular Carcinoma not amenable to curative therapies will provide greater efficacy than chemoembolization alone with a tolerable safety profile.
What is the current status of trial NCT02524119?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2016-04. Estimated completion is 2020-09.
What interventions are being tested in trial NCT02524119?
The interventions under investigation include: LEE011 (DRUG), Chemoembolization (PROCEDURE).
Who is sponsoring clinical trial NCT02524119?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.